RxDoctor Payments Data

Mariette Austin, MD

Medical Oncology · Easton, PANPI 1992703516

Payments from drug & device makers

$312in general payments, 2019–2025

Across 11 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$84
  • Incyte Corporation$80
  • Amgen$74
  • Pharmacyclics LLC, An Abbvie Company$18
  • Johnson & Johnson$17
  • Pfizer$15
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$13644%
  • Education$17656%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$312 in reported general payments places this provider in the 20th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$116,829
Medicare patients
399
Services billed
1,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib17$404,578
CalquenceAcalabrutinib Maleate41$365,673
PomalystPomalidomide13$346,096
InrebicFedratinib Dihydrochloride13$335,526
RevlimidLenalidomide15$297,835
JakafiRuxolitinib Phosphate13$296,239
VenclextaVenetoclax12$157,765
PromactaEltrombopag Olamine12$157,370
LynparzaOlaparib13$115,556
EliquisApixaban21$18,258
Abiraterone Acetate40$17,030
XareltoRivaroxaban15$12,504
Letrozole127$4,378
Tamoxifen Citrate111$3,879
Hydroxyurea55$1,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Lynparza$84$481,22954 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$18$404,57817 claims
Incyte CorporationJakafi$80$296,23913 claims
NovartisPromacta$12$157,37012 claims
PfizerEliquis$15$18,25821 claims
Johnson & JohnsonXarelto$17$12,50415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 238 medical oncology providers in Pennsylvania.

Other medical oncology in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →